Gene Therapy & Rare Diseases
Unparalleled manufacturing expertise in the hottest therapeutic areas of biotech
Whether is it insect, transient mammalian, or virus mediated rAAV production, Paragon has experience scaling-up and developing a process tailored towards our client’s bottom line. Your technology is not cookie cutter; why should your manufacturing process be?
Over the years, Paragon has helped its clients move from an adherent culture into a scalable, suspension-based process utilizing serum-free/animal-free components. (Serotypes 1, 2, 5, 6, 8, 9, & 10).
>75% of our current contracts are for Gene Therapy
There is a strong global demand for rAAV manufacturing and only limited CDMO capacity